Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Urgente. Acción COST: Búsqueda de empresa especializada en implantes para transformar complejos de adhesión celular en blancos terapéuticos

Resumen

Tipo:
Búsqueda de socios
Referencia:
RDUK20161103001
Publicado:
04/11/2016
Caducidad:
04/11/2017
Resumen:
Una universidad británica participa en un consorcio en la acción COST (Cooperación Europea en Ciencia y Tecnología) con el fin de identificar componentes cruciales de complejos de adhesión celular (CAC) que sirvan como nuevos blancos terapéuticos para diversas enfermedades. El consorcio busca una compañía europea especializada en dispositivos implantables, nanopatterning y disciplinas bioterapéuticas interesada en participar en el consorcio. La fecha límite de la convocatoria es el 17 de noviembre de 2016 y el plazo para presentar expresiones de interés finaliza el 15 de noviembre.

Details

Tittle:
URGENT: COST action - Seeking implant company to transform cell adhesion complexes to therapeutic targets
Summary:
A UK university is part of a COST (European Cooperation in Science and Technology) Action consortium aimed at identifying crucial components of cell adhesion complexes (CACs) serving as novel therapeutic targets for different diseases. The consortium are seeking a European company working with implantable devices, nanopatterning or biotherapeutics to join this under a research cooperation agreement.
Description:
CACs consist of clusters of transmembrane receptors that bind to extracellular matrix (ECM) components and neighbouring cells outside the cell while anchoring intracellular cytoskeletal structural proteins and signal transduction molecules on the inside.

CACs are dynamic structures that sense physical and biochemical cues from the environment and transmit such information to the cell interior to regulate cell shape and function. In normal tissue, the compositions of CACs are tightly regulated but changes in the expression or activity of many of their components is associated with a variety of human diseases. Interventions targeting CACs components represent a potentially important therapeutic approach. To reach the full societal and economical potential of therapeutic strategies targeting CACs, the diversity of excellent science in this field must become more integrated and coupled to clinical application.

COST is the longest-running European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe. COST Actions allow European researchers to jointly develop their own ideas in any science and technology field. COST funds pan-European, bottom-up networks of scientists and researchers across all science and technology fields. These networks, called ´COST Actions´, promote international coordination of nationally-funded research. COST is supported by the EU Framework Programme Horizon 2020.

This consortium and COST action (known as CellAC) aims to establish a network to unify the complementary expertises of world-class CACs fundamental researchers and clinicians in Europe. The group already consists of 53 partners, including German, Swiss, Swedish, Dutch, Cypriot, UK, Italian, American, Greek, Austrian, Norwegian, Czech, French, Israeli, and Crotian universities, a German company and a Spanish, Greek, and Scottish research institute.

They are seeking an additional industry partner from within the EU to join the bid as part of a research cooperation agreement, that currently has experience working in one or more of the following areas:

- Nanopatterning
- Implantable devices
- Diagnostics
- Drug discovery
- Imaging development
- Biotherapeutics

It is anticipated that the company will be able to contribute towards a greater understanding of the function of CACs proteins that will enable identification of key therapeutic attack-points in CACs.

The deadline for the bid is 17 November 2016 and the deadline for expressions of interest in this call is 15 November 2016.

Partner sought

Partner Sought:
Type: Industry Activity: Biomedical devices, implants, biotherapeutics Specific role of partner in this project: To contribute expertise, tools and devices for ongoing testing or trials, medical research. To interact with academic scientists to explore translation of basic research into medical applications.
Type of Partnership Considered:
RDR

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English

Dissemination

Programme-call

Evaluation Scheme:
Single stage
Coordinator Required:
No
Deadline for Call:
17/11/2016
Project Duration:
0
Project title and Acronym:
CellAC